What gene-editing technology was used in a new UCLA technique to 'unlock' immune cells against solid tumors in February 2026?

In February 2026, a groundbreaking technique developed by UCLA researchers utilized CRISPR gene-editing technology to enhance the ability of immune cells to combat solid tumors. The research focused on "unlocking" the natural power of immune cells, specifically Natural Killer (NK) cells, by deleting a gene called FLI1. This precise genetic modification significantly improved the NK cells' survival and their capacity to infiltrate and inhibit the growth of solid tumors in preclinical studies.

CRISPR, an acronym for Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that acts like molecular scissors. It allows scientists to make incredibly precise changes to DNA, including deleting specific genes or inserting new genetic material. This level of accuracy is what makes CRISPR so powerful for therapeutic applications, enabling researchers to modify cells with targeted interventions. In the context of cancer, solid tumors present a formidable challenge to the immune system due to their dense protective barriers and ability to create an inhospitable environment for immune cells.

By using CRISPR to remove the FLI1 gene, the UCLA team effectively removed a "brake" on the immune system, allowing the NK cells to better withstand the harsh conditions within solid tumors and maintain their cancer-fighting capabilities. This innovative approach holds significant promise for future immunotherapies, potentially leading to more effective treatments for a wide range of solid cancers where traditional therapies have struggled. The ongoing research aims to translate these findings into clinical applications, offering new hope for patients.